Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Horizon Pharma Rheumatology LLC | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The objective of this research is to evaluate the correlation between DECT and US explorations performed in a routine clinical setting for the measurement of change in tophus size in gout patients after 24 months of treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| UltraSonography and DECT | Experimental | UltraSonography and DECT will be used in patient monitoring after 6, 12 and 24 months of treatment in order to evaluate the correlation between the 2 explorations for the measurement in tophus volume change. Those are interventions that are not part of the standard care of the patients. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ultrasonography | Procedure | The tophus volume will be assess using ultrasonography. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Correlation between US and DECT measurement of change in tophus volume | Spearman rank correlation between the change in tophus volume after 24 months of treatment measured by ultrasonography or by DECT. | after 24 months of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Correlation between US and DECT measurement of change in tophus volume | Spearman rank correlation between the change in tophus volume after 6, 12 and 24 months of treatment measured by ultrasonography or by DECT. | after 6 months, 12 months and 24 months of treatment |
| Change of DECT urate score |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Tristan Pascart, MD | Hospital Group of the Catholic Institute of Lille | Study Director |
| Sébastien Ottaviani, MD | Bichat Hospital of Paris | Principal Investigator |
| Pascal Richette, MD PhD | Lariboisiere Hospital of Paris | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Group of the Catholic Institute | Lomme | 59462 | France | |||
| Bichat Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40139560 | Result | Pascart T, Richette P, Bousson V, Ottaviani S, Ea HK, Liote F, Latourte A, Bardin T, Ora J, Pacaud A, Vandecandelaere M, Luraschi H, Jauffret C, Laurent V, Boissel M, Norberciak L, Legrand J, Lefevre G, Ducoulombier V, Budzik JF. Time-course of tophus resolution on Dual-energy CT and ultrasound after 24months of a treat-to-target strategy: Results from GOUT-DECTUS study. Joint Bone Spine. 2025 Jul;92(4):105892. doi: 10.1016/j.jbspin.2025.105892. Epub 2025 Mar 24. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006073 | Gout |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D000070657 | Crystal Arthropathies |
Not provided
Not provided
| ID | Term |
|---|---|
| D019220 | High-Energy Shock Waves |
| ID | Term |
|---|---|
| D000069453 | Ultrasonic Waves |
| D013016 | Sound |
| D011840 | Radiation, Nonionizing |
| D011827 | Radiation |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| DECT | Procedure | The tophus volume will be assess using dual-energy computed tomography (DECT). |
|
|
Change from baseline after 6, 12 and 24 months of treatment in DECT urate score |
| after 6 months, 12 months and 24 months of treatment |
| Link between the change of DECT urate score and the persistence of the double contour sign | During ultrasonography, a double contour of the articulation can be visible. This outcome will compare the change in the DECT urate score between the patients for who the double contour stay visible and those for who it disapear. This outcome register if this double contour stay visible. | after 6 months, 12 months and 24 months of treatment |
| Correlation between the change of DECT urate score and the change in serum uric acid levels | The Spearman correlation between the change from baseline of the DECT urate score and the serum uric acid levels will be computed for each time point. | after 6 months, 12 months and 24 months of treatment |
| Correlation between the change of DECT urate score and the number of gout attacks | The Spearman correlation between the change from baseline of the DECT urate score and the number of gout attack will be computed. | after 6 months, 12 months and 24 months of treatment |
| Paris |
| 75018 |
| France |
| Lariboisière Hospital | Paris | 75475 | France |
| D012216 |
| Rheumatic Diseases |
| D011686 | Purine-Pyrimidine Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D055585 |
| Physical Phenomena |